Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Figure 4 shows the forest plots of the six CVOTs that reported the evaluation of MACE risk as a sub-analysis of patients with T2DM divided according to the presence or absence of CV disease at baseline, respectively
Remarkably, beneficial effects have been observed across this 100-fold range, suggesting a wide therapeutic window where smaller doses remain biologically active
Nayan Patel question for you
It's not the research itself
Caddy GR, Johnston CF, Ardill JES, Pogue KM, Collins JSA, Gardiner KR, Watson PR (2001) Distribution of glucagon-like peptide-2 (GLP-2) in normal colonic tissue
Outcomes were evaluated at six months
US$ 20.45
US$ 20.26
US$ 20.71
US$ 27.43
